A Prospective Randomized Comparative Clinical Study to Evaluate the Efficacy of Cresvin Beta Capsules in Type II Diabetes Mellitus Patients

Apex Laboratories Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年5月30日

试验速览

暂无简介。

•Male or female patients within the age range of 18 to 60 years (both years inclusive) diagnosed with T2DM for at least 3 months.
•-Willingness to provide written informed consent to participate in the study.
•-Patients understanding the nature and purpose of the study and who are willing to comply with study procedures.
•-Fasting plasma glucose greater than or equal to 126 mg/dL
•-Random plasma glucose greater than 200 mg/dL in a person with symptoms of diabetes.
•-Duration of diabetes â?? Newly diagnosed diabetics or diagnosed within past 5 years
•-HbA1C between 7-9.5%

•-Type 1 diabetes mellitus
•-Patients with severe hyperglycemia (FBS greater than 234 mg per dl or PPBS greater than 360 mg per dl
•-HbA1C is more than 9.5 per cent.
•-ASAT and ALT levels greater than 2.5 times the upper normal limits
•ï?§Severe renal, hepatic, cardiac, gastrointestinal, neurological, hematological or respiratory
•ï?§disorders, in view of the investigator.
•ï?§Patients with psychiatric disorder.
•ï?§History of smoking (more than 10 cigarettes/day) or alcohol intake > 20gm/day.

发起方